CLINICAL STUDY: CARDIOMYOPATHY
Effect of beta-blockers on circulating levels of inflammatory and anti-inflammatory cytokines in patients with dilated cardiomyopathy
Tomoaki Ohtsuka, MDa,
Mareomi Hamada, MD, FACCa,
Go Hiasa, MDa,
Osamu Sasaki, MDa,
Makoto Suzuki, MDa,
Yuji Hara, MDa,
Yuji Shigematsu, MDa and
Kunio Hiwada, MDa
a Second Department of Internal Medicine, Ehime University School of Medicine, Ehime, Japan
Manuscript received June 5, 2000;
revised manuscript received August 23, 2000,
accepted October 3, 2000.
Reprint requests and correspondence: Dr. Tomoaki Ohtsuka, Second Department of Internal Medicine, Ehime University School of Medicine, Shigenobu, Onsen-gun, Ehime 791-0295, Japan mhamada{at}m.ehime-u.ac.jp
OBJECTIVES
This study was designed to evaluate the beneficial effect of beta-blockers on circulating cytokine levels in patients with dilated cardiomyopathy (DCM).
BACKGROUND
Elevated circulating levels of inflammatory cytokines have been reported in patients with DCM. However, alterations of the levels of inflammatory and anti-inflammatory cytokines in association with beta-blocker therapy are unknown.
METHODS
We studied 32 patients with idiopathic DCM who had been treated with digitalis, diuretics and angiotensin-converting enzyme inhibitors. In addition to this combination therapy, beta-blockers were started in all patients. Serum levels of interleukin (IL)-10, tumor necrosis factor-alpha (TNF-alpha) and soluble TNF receptors (sTNF-R1 and R2) were measured at baseline and 12 weeks after the initiation of beta-blocker therapy. We also measured plasma levels of neurohumoral factors, as well as left ventricular (LV) size and function. Ten age-matched subjects with no cardiac disease served as the control group.
RESULTS
Baseline levels of IL-10, TNF-alpha and sTNF-R2 were significantly higher in patients with DCM than in control subjects (p < 0.05). There was a significant positive correlation between IL-10 and TNF-alpha levels (r = 0.545, p = 0.029). The TNF-alpha/IL-10 ratio correlated well with plasma epinephrine levels (r = 0.677, p = 0.025), and the level of sTNF-R2 was closely related to LV size. Serum levels of IL-10, TNF-alpha and sTNF-R2 were significantly decreased during beta-blocker therapy (p < 0.005).
CONCLUSIONS
Our findings indicate that beta-blockers have an important immunoregulatory role in modifying the dysregulated cytokine network in DCM. This effect of beta-blockers may be partly responsible for the efficacy of therapeutic drugs for heart failure.
|
Abbreviations and Acronyms
| | ACE | = angiotensin-converting enzyme | | ANP | = atrial natriuretic peptide | | BNP | = brain natriuretic peptide | | CHF | = congestive heart failure | | DCM | = dilated cardiomyopathy | | EDD | = end-diastolic dimension | | ESD | = end-systolic dimension | | IL | = interleukin | | LV | = left ventricular | | sTNF-R | = soluble tumor necrosis factor receptor | | TNF-alpha | = tumor necrosis factor-alpha |
|
This article has been cited by other articles:

|
 |

|
 |
 
M. D. Kertai, C. M. Westerhout, K. S. Varga, G. Acsady, and J. Gal
Dihydropiridine calcium-channel blockers and perioperative mortality in aortic aneurysm surgery
Br. J. Anaesth.,
October 1, 2008;
101(4):
458 - 465.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. Liuba, H. Ahlmroth, L. Jonasson, A. Englund, A. Jonsson, K. Safstrom, and H. Walfridsson
Source of inflammatory markers in patients with atrial fibrillation
Europace,
July 1, 2008;
10(7):
848 - 853.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Poldermans, S. E. Hoeks, and H. H. Feringa
Pre-Operative Risk Assessment and Risk Reduction Before Surgery
J. Am. Coll. Cardiol.,
May 20, 2008;
51(20):
1913 - 1924.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Loppnow, K. Werdan, and M. Buerke
Invited review: Vascular cells contribute to atherosclerosis by cytokine- and innate-immunity-related inflammatory mechanisms
Innate Immunity,
April 1, 2008;
14(2):
63 - 87.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
L Dubey and Z Hesong
Anti-inflammatory action of diltiazem in patients with unstable angina.
Postgrad. Med. J.,
September 1, 2006;
82(971):
594 - 597.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. S Schleithoff, A. Zittermann, G. Tenderich, H. K Berthold, P. Stehle, and R. Koerfer
Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial.
Am. J. Clinical Nutrition,
April 1, 2006;
83(4):
754 - 759.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. J. Boos and G. Y.H. Lip
Is atrial fibrillation an inflammatory disorder?: reply
Eur. Heart J.,
April 1, 2006;
27(7):
886 - 886.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Odeh, E. Sabo, and A. Oliven
Circulating levels of tumor necrosis factor-{alpha} correlate positively with severity of peripheral oedema in patients with right heart failure
Eur J Heart Fail,
March 1, 2006;
8(2):
141 - 146.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. H. Spodick
Decreased Recognition of the Post-Myocardial Infarction (Dressler) Syndrome in the Postinfarct Setting: Does It Masquerade as "Idiopathic Pericarditis" Following Silent Infarcts?
Chest,
November 1, 2004;
126(5):
1410 - 1411.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Z. Yuan, K. Shioji, Y. Kihara, H. Takenaka, Y. Onozawa, and C. Kishimoto
Cardioprotective effects of carvedilol on acute autoimmune myocarditis: anti-inflammatory effects associated with antioxidant property
Am J Physiol Heart Circ Physiol,
January 1, 2004;
286(1):
H83 - H90.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Zoccali, F. Mallamaci, and G. Tripepi
Novel Cardiovascular Risk Factors in End-Stage Renal Disease
J. Am. Soc. Nephrol.,
January 1, 2004;
15(90010):
S77 - 80.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
S. Adamopoulos, J. T. Parissis, I. Paraskevaidis, D. Karatzas, E. Livanis, M. Georgiadis, G. Karavolias, D. Mitropoulos, D. Degiannis, and D. Th. Kremastinos
Effects of growth hormone on circulating cytokine network, and left ventricular contractile performance and geometry in patients with idiopathic dilated cardiomyopathy
Eur. Heart J.,
December 2, 2003;
24(24):
2186 - 2196.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. S. Beattie, M. G. Shlipak, H. Liu, W. S. Browner, N. B. Schiller, and M. A. Whooley
C-Reactive Protein and Ischemia in Users and Nonusers of {beta}-Blockers and Statins: Data From the Heart and Soul Study
Circulation,
January 21, 2003;
107(2):
245 - 250.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. O. Weinberg, M. Shimpo, G. W. De Keulenaer, C. MacGillivray, S.-i. Tominaga, S. D. Solomon, J.-L. Rouleau, and R. T. Lee
Expression and Regulation of ST2, an Interleukin-1 Receptor Family Member, in Cardiomyocytes and Myocardial Infarction
Circulation,
December 3, 2002;
106(23):
2961 - 2966.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. J. Pugh, R. D. Jones, T.H. Jones, and K. S. Channer
Heart failure as an inflammatory condition: potential role for androgens as immune modulators
Eur J Heart Fail,
December 1, 2002;
4(6):
673 - 680.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Jones and H. Montgomery
The Gly389Arg beta-1 adrenoceptor polymorphism and cardiovascular disease: time for a rethink in the funding of genetic studies?
Eur. Heart J.,
July 2, 2002;
23(14):
1071 - 1074.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Adamopoulos, J. Parissis, D. Karatzas, C. Kroupis, M. Georgiadis, G. Karavolias, J. Paraskevaidis, K. Koniavitou, A. J. S. Coats, and D. T. Kremastinos
Physical training modulates proinflammatory cytokines and the soluble Fas/soluble Fasligand system in patients with chronic heart failure
J. Am. Coll. Cardiol.,
February 20, 2002;
39(4):
653 - 663.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S Moller and J H Henriksen
Cirrhotic cardiomyopathy: a pathophysiological review of circulatory dysfunction in liver disease
Heart,
January 1, 2002;
87(1):
9 - 15.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. P. Bolger, R. Sharma, P. Aukrust, L. Gullestad, H. Aass, J. G. Fjeld, L. Wikeby, A. K. Andreassen, H. Ihlen, S. Simonsen, et al.
Increase in Anti-Inflammatory Cytokine Levels in Chronic Heart Failure: A Measure of Treatment Success or Failure? Response
Circulation,
October 30, 2001;
104
(18):
e97 - e97.
[Full Text]
[PDF]
|
 |
|
|